Blend review · Muscle & strength

CJC/Ipamorelin

The references concern separately studied components. They do not demonstrate that this combination has the same effects, additive effects or a particular safety profile.

By HeartPep · Reviewed · 2 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

Selected human studies establish component-level endocrine observations. No trial of the exact catalogue blend was verified for this entry.

Identity & scope

The supplier label names CJC and ipamorelin but does not establish the CJC form, exact sequences or component proportions. These details are material to interpreting the literature.

Catalogue labels covered: CJC/Ipamorelin.

What the research shows

  • A component study can generate a hypothesis for a combination experiment. It cannot supply that experiment’s result.

Critical interpretation

A plausible combination remains a separate experimental claim

The component papers show that each specified research preparation can change a GH-related endpoint. Neither assigns participants to the catalogue combination. An effect from one component, or an interaction between pathways, cannot be quantified by putting results from separate studies side by side. A useful combination study would need the mixture characterised and suitable single-component comparisons, so that any additional effect could be distinguished from either component’s contribution. This is a study-design requirement inferred from the evidence gap, not a result reported by these papers. [1] [2]

Identity uncertainty comes before an effect estimate

The CJC paper concerns a long-acting albumin-binding analogue; the blend name does not establish that this is its CJC constituent. The ipamorelin paper concerns a single peptide preparation. Consequently, even the starting molecular comparison remains incomplete. A defensible review of the exact blend would need confirmed component identities and proportions before examining mixture-specific stability, exposure or outcomes. Component evidence remains useful background, with its limits kept visible. [1] [2]

Limitations & uncertainties

  • The studied long-acting CJC form may differ from the blend.
  • Component findings do not establish chemical compatibility, stability, absorption or outcomes for a combined vial or spray.

Open research questions

  • Which CJC analogue and component proportions are documented?
  • Has the exact mixture been independently characterized and tested in a relevant model?

Selected papers & source records

Download bibliography
Human studyComponent evidenceAbstract / record checked

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab)

Teichman SL, Neale A, Lawrence B, et al. (2006). Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/jc.2005-1536 (opens in a new tab) · PMID 16352683

Design & population
Two randomized, double-blind, placebo-controlled ascending-exposure trials, lasting 28 and 49 days, in healthy adults aged 21–61.
What the study found
The defined long-acting analogue produced sustained increases in GH and IGF-I. Its estimated half-life was 5.8–8.1 days.
Limits on interpretation
This study tested a defined long-acting CJC-1295 analogue alone. It did not test a CJC/ipamorelin blend, and the catalogue does not establish which CJC form the blend contains.
Human studyComponent evidenceAbstract / record checked

2. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (opens in a new tab)

Gobburu JV, Agersø H, Jusko W, Ynddal L. (1999). Pharmaceutical Research. DOI: 10.1023/a:1018955126402 (opens in a new tab) · PMID 10496658

Design & population
Dose-escalation infusion experiment with eight healthy male volunteers at each of five exposure levels.
What the study found
A short GH-release episode followed ipamorelin exposure; the investigators developed a model relating drug concentration to GH response.
Limits on interpretation
Ipamorelin-alone hormone pharmacology cannot establish the behaviour, compatibility, efficacy or safety of a CJC/ipamorelin blend.

Search & review scope

Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.

Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.

Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.

Recorded search terms
  • site.pubmed.ncbi.nlm.nih.gov 16352683 CJC-1295 Teichman
  • site.pubmed.ncbi.nlm.nih.gov ipamorelin randomized postoperative ileus trial
  • site.pubmed.ncbi.nlm.nih.gov "CJC-1295" "ipamorelin" trial

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. CJC/Ipamorelin: blend review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/cjc-ipamorelin.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes